Skip to main content

BioMedPartners closes new venture capital fund

| News

BioMedPartners closes new venture capital fund

06.03.2018

Basel-based venture capitalist firm BioMedPartners has closed its new venture capital fund BioMedInvest III at 100 million Swiss francs. The fund will help drive growth in the Swiss life science cluster by investing in private early-to-mid-stage companies.

BioMedPartners

Main investors in the BioMedInvest III healthcare venture capital fund are the European Investment Fund (EIF) and the Berner Kantonalbank (BEKB). According to Markus Hosang, General Partner at BioMedPartners, his company also succeeded in gaining the Basellandschaftliche Kantonalbank (BLKB) and several important individuals as new investors.

“We are proud of having established BioMedPartners as a leading venture group and early-stage life science investor in Europe over the last 15 years since its inception,” added Thomas Möller, General Partner at BioMedPartners. “The successful closing of our third equity venture fund is also a major milestone for the future growth of the Life Science Cluster in Switzerland.”

The Basel-based company will invest 100 million Swiss francs in 12 to 15 biopharmaceutical, medical device and diagnostics companies. It will also take an active role in these companies by providing its expertise and access to its network of industry experts and scientific leaders.

The fund’s focus is on Swiss companies as well as those from neighbouring countries. For instance, its first three investments are: Allecra Therapeutics, a French antibiotics company based in the Basel area, Amal Therapeutics in Geneva, and the German biotech company Cardior Pharmaceuticals.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.